Dr. Don Brown is the most successful serial software entrepreneur in the Midwest. His first company was acquired by EDS in 1986. He founded Software Artistry in 1988 which became the first software company in Indiana ever to go public and was later acquired by IBM for $200 million. Don then founded and served as CEO of Interactive Intelligence which went public in 1999 and was acquired by Genesys Telecommunications Laboratories in 2016 for $1.4 billion. Read his full bio.

Interview with Don Brown from LifeOmic

Q: What need is LifeOmic addressing?

A: Precision Medicine requires the aggregation of huge data sets, including data representing individual patients from the level of their genomes all the way up through various levels of their phenomes. LifeOmic has created a cloud-based platform that can combine such data for millions of patients, including data from electronic medical records to genetic tests, diagnostic images and even mobile fitness tracker data. Powerful machine learning capabilities allow LifeOmic customers such as healthcare providers and medical researchers to identify new biomarkers, analyze trends and even predict health problems before they are clinically diagnosed.

Q: What are the products and/or services LifeOmic offers/develops to address this need? What makes LifeOmic unique?

A: In addition to a cloud platform capable of aggregating, indexing and analyzing all types of patient information, LifeOmic has created a complementary mobile app called LIFE Extend for population health and personal wellness. With this app, individuals can combine telemetry data from fitness trackers and other mobile devices with their medical records, genetic tests and other health information. LifeOmic’s “AI in the sky” can continuously monitor each individual, calculate a precise “biological age,” and offer personalized recommendations to realize the potential of precision health. The LIFE Extend app also leverages gamification and social interaction to make it fun to use. With LIFE Extend, LifeOmic can offer providers and researchers direct access to patients, many of whom are willing to share all of their medical information to further research.

Q: What is your role at LifeOmic and what excites you about your work?

A: I’m the founder and CEO of LifeOmic. After earning an MD and a graduate degree in computer science, I spent three decades building large software companies that had nothing to do with the life sciences. With the sale of my most recent company – Interactive Intelligence (NASDAQ:ININ) for $1.4B in 2016, I was finally free to assemble a world class team spanning cloud software development, machine learning, security, genetics, bioinformatics, cancer and mobile apps in forming LifeOmic. After 18 months working largely in stealth mode with disease teams at the Indiana University School of Medicine, we’re finally ready to show off what our nearly 50 scientists and engineers have created.

Q: When thinking about LifeOmic and the domain LifeOmic is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: LifeOmic has been fortunate to lie at the nexus of three exponential trends – genomics, cloud computing and machine learning. For the first time in history it’s possible to assemble a comprehensive view of a human being from their germline whole genome sequence through various levels of phenotype (gene expression, molecular biomarkers, physiologic measurements, etc.). With cloud computing and machine learning, we can aggregate this information across millions of people and tease out hidden trends and associations. The field has been talking about “personalized” or “precision” medicine for a long time. Now we can finally deliver exactly that.

Q: What are the short-term challenges that LifeOmic and its peers are facing?

A: Perhaps one of the biggest challenges is keeping up with the explosion of new information – gene variations and their pathologic significance, protein-protein interactions, signaling pathways, etc. At LifeOmic, we’ve invested heavily in building a feature codenamed Gnosis that continuously pulls information from public data sets all over the world so that they can be used within our platform. This allows clinicians and researchers to understand patient information within the context of the latest knowledge available – whether for understanding which mutations are driving a patient’s cancer or which combination of approved small molecules might inhibit an overactive signaling pathway.

Q: Is there anything else you would like to share with the PMWC audience?

A: LifeOmic, we think there’s a huge need for a cloud-based platform that can inexpensively store huge amounts of patient data and apply the latest machine learning tools to it. That’s what we’ve built with the Precision Health Cloud. By taking an API-first approach, we’ve tried to make the platform simple to get started with, easy to access and extremely extensible. Our cloud has become the lynchpin of the Indiana University Precision Health Initiative. We’re hoping to develop additional collaborations to help make the tremendous promise of precision medicine a reality.

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!